Guideline / position statementindependent cross-checkabstract checked★ key study I-ODD-126 in-depth review
NICE 2026: offer metformin plus an SGLT-2 inhibitor to most adults with type 2 diabetes
Type 2 diabetes in adults: management (NICE guideline NG28), published 2 December 2015, last updated 18 February 2026
Overview
National Institute for Health and Care Excellence (NICE). NICE guideline 2026
Fewer heart events and heart-failure admissions; DKA and Fournier gangrene 1 per 1,000 or fewer.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Recommend first-line diabetes medicines.
- How was the study done?
Guideline based on meta-analyses.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Benefits outweigh risks for most people.
- How large was the observed effect?
HF hospitalisation 54 vs 26-40 per 1,000 over 3 years.
- What do the results mean in everyday life?
These medicines are recommended because they prevent heart problems.
- What are the study's limitations?
UK context.
- What does it say about Elawady's specific claim?
Contradicts net harm.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual choices.
Scientific in-depth review
1. Full reference
- Authors
- National Institute for Health and Care Excellence (NICE)
- Journal
- NICE guideline
- Year
- 2026
- Identifier
- Verification
- verified – Web pages fetched 2026-10-26 (chapters 'Initial medicines' and 'Recommendations for research')
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Public body; committee interests declared on NICE site (not reviewed).
2. Research question
Which medicines should adults with type 2 diabetes be offered first?
3. Study design and population
- Study design
- Guideline / position statement – National clinical guideline based on network and pairwise meta-analyses and health economic modelling (relevant chapters read)
- Population
Adults with type 2 diabetes
- Country
England/UK
- Period
2026 update
- Sample size
Not applicable
- Inclusion and exclusion criteria
Not applicable
4. Methods and endpoints
- Exposure / intervention
Metformin, SGLT-2 inhibitors, GLP-1 RAs and others
- Comparator
Not applicable
- Endpoints
MACE, heart failure hospitalisation, adverse events
- Statistical methods
Not applicable
5. Actual results
- Results
Rec 1.13.1: for adults with type 2 diabetes and no relevant comorbidity, offer modified-release metformin and an SGLT-2 inhibitor [2026]; 1.13.2: if metformin is contraindicated, offer SGLT-2 inhibitor monotherapy. Evidence summary: 3-item MACE 123 vs 107-115 per 1,000 over 3 years; heart-failure hospitalisation 54 vs 26-40 per 1,000; 1 in 1,000 or fewer would experience rarer events like DKA or Fournier gangrene; committee agreed benefits outweigh risks for most people.
- Absolute risks
DKA or Fournier gangrene: 1 per 1,000 or fewer.
- Authors' conclusion
Metformin plus an SGLT-2 inhibitor is the most clinically effective standard initial treatment.
6. Strengths
- Independent national body
- Absolute effects presented
7. Weaknesses
- UK cost context
- Only selected chapters read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline.
9. Assessment of the statistical interpretation
Absolute benefit (about 8-16 fewer MACE and 14-28 fewer HF hospitalisations per 1,000 over 3 years) exceeds rare harms (<=1 per 1,000).
10. Relevance to the specific claim
Current European-region guideline position that directly contradicts 'net harmful' and quantifies DKA/Fournier as rare.
11. Independent contrary findings
None.
12. Transferability to Germany and Europe
High (UK).
13. Overall methodological judgement
Authoritative 2026 statement.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None.
15. Linked fact checks
- Glucose-lowering drugs are net harmful and belong among the 'forbidden' items; dapagliflozin (Forxiga) is among the 'dirtiest' drugs and kills the brain; leg amputations happen only to people taking diabetes drugs and insulin. – Studies contradicting or limiting the claim
- SGLT2 inhibitors such as dapagliflozin (Forxiga) can cause ketoacidosis, sometimes with normal or low blood glucose. – Studies with mixed or unclear results
- Every major class of glucose-lowering drug (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists) carries a documented signal of serious harm in the peer-reviewed literature. – Studies contradicting or limiting the claim